• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Gilead Sciences

Gilead Sciences

Gilead Sciences Inc GILD

Last Price$82.29Day Change (%)-0.82%
Open Price$83.39Day Change ($)-0.68
Day Range82.13–83.3952-Week Range63.76–86.27

As of Tue 9/19/2017 5:31:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences , Inc . is Fair to Shareholders

    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Kite Pharma, Inc. to Gilead Sciences , Inc . is Fair to Shareholders

  2. Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6

    Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6

  3. Gilead Prices $3 Billion of Senior Unsecured Notes

    Gilead Prices $3 Billion of Senior Unsecured Notes

  4. Global Angina Pectoris Treatment Market (2017-2025): By Drug Class & Geography - Research and Markets

    Global Angina Pectoris Treatment Market (2017-2025): By Drug Class & Geography - Research and Markets

  5. UPDATE: Dow buffeted by Travelers stock in Hurricane Harvey's wake

    UPDATE: Dow buffeted by Travelers stock in Hurricane Harvey's wake

  6. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  7. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

  8. UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

    UPDATE: Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

12345

©2017 Morningstar Advisor. All right reserved.